Opinion statement Treatment of early stage breast cancer requires a multimodality approach
in order to eradicate residual cancer and prevent recurrent disease. Targeting the pathways …

Background A reliable preclinical model of patient-derived organoids (PDOs) was
developed in a case study of a 69-year-old woman diagnosed with breast cancer (BC) to …

Simple Summary The development of HER2-inhibitors for the treatment of HER2-positive
breast cancer represented a breakthrough in targeted tumor therapy. However, as for other …

A majority of breast cancers (BC) display characteristics of epithelial cells and express
estrogen receptors and/or HER-2 (a member of the epidermal growth factor receptor family) …

89Zr-labeled antibodies are being investigated in several clinical trials; however, the time
requirement for synthesis of clinical doses can hinder patient throughput because of …

Simple Summary Evidence on cardiotoxicity prevention and treatment strategies in patients
receiving anthracyclines or HER2 receptor inhibitors, vital treatments for breast cancer and …

Urothelial carcinoma (UC) is a common cancer characterized by high morbidity and mortality
rates. Despite advancements in treatment, challenges such as recurrence and low response …

Objectives: Therapeutic monoclonal antibody biosimilars are expected to help reduce the
sizeable economic burden of targeted treatments. Trastuzumab (Herceptin®), a recombinant …

The elucidation of the human genome and advances in knowledge about molecular
abnormalities, signaling pathways, influence of the local tissue milieu and the relevance of …

Monoclonal antibodies (mAbs) are being used to prevent, detect, and treat a broad spectrum
of malignancies and infectious and autoimmune diseases. Over the past few years, the …